Even with astounding advances in genomic science, genetic analysis of disease remains largely a measure of risk rather than actual disease state. A truer and more immediate measure of health can be obtained by analysis of proteins, especially those that are biomarkers of disease state. Until now, proteomic technologies have lacked the sensitivity, scale, and robustness to untangle the vast differences in protein types and concentration levels that underlie complex human biology and disease. In two papers published on December 2 in the open-access scientific journal PLoS One, researchers at SomaLogic, Inc., and their collaborators describe a revolutionary new approach to biomarker detection and demonstrate its potential diagnostic power in a large-scale study that identifies a panel of biomarkers that can detect lung cancer in its early and treatable stages.
Personalized medicine has to be more than prediction of risk for disease, it has to be actionable; what is the persons state of health at this moment? To determine that you have to understand what proteins are being made, and at what concentrations, even at very low levels, said Larry Gold, Founder, Chairman and CEO of SomaLogic. This has proven to be a difficult task, but we believe we have succeeded at finding a way to entirely transform protein-based diagnostics and help drive the realization of personalized medicine in this decade.
SomaLogics proteomic technology is built on two decades of painstaking work to corral aptamers short stretches of nucleic acids that form protein-binding three-dimensional structures into performing exquisitely specific recognition and binding of proteins. Through a series of chemical modifications of the nucleic acids that make up the aptamer, SomaLogic scientists were able to develop a next generation of aptamers renamed SOMAmers to reflect their increased abilities -- that together can bind proteins of widely diverse types and concentrations. And because
|Contact: Jeff Walker|